Table 2. Antimicrobial susceptibility testing among bla _NDM-1-carrying isolates and their transconjugants.

Antibiotics	Patient 1		Patient 2
	E. coli	Transconjugant	K. pneumoniae	Transconjugant
Ampicillin	≥32 µg/ml	≥32 µg/ml	≥32 µg/ml	≥32 µg/ml
Cefazolin	≥32 µg/ml	≥32 µg/ml	≥32 µg/ml	≥32 µg/ml
Cefotaxime	≥64 µg/ml	≥64 µg/ml	≥64 µg/ml	≥64 µg/ml
Ceftazidime	≥32 µg/ml	≥32 µg/ml	≥32 µg/ml	≥32 µg/ml
Cefepime	≥32 µg/ml	≥32 µg/ml	≥32 µg/ml	≥32 µg/ml
Aztreonam	≥32 µg/ml	≥32 µg/ml	≥32 µg/ml	≥32 µg/ml
Cefoxitin	≥32 µg/ml	≥32 µg/ml	≥32 µg/ml	≥32 µg/ml
Ertapenem	≥8 µg/ml	≥8 µg/ml	≥8 µg/ml	≥8 µg/ml
Imipenem	≥8 µg/ml	≥8 µg/ml	≥8 µg/ml	≥8 µg/ml
Meropenem	≥8 µg/ml	≥8 µg/ml	≥8 µg/ml	4 µg/ml
Doripenem	≥8 µg/ml	≥8 µg/ml	≥8 µg/ml	≥8 µg/ml
Ciprofloxacin	≥4 µg/ml	≤0.06 µg/ml	≥4 µg/ml	≤0.06 µg/ml
Gentamicin	≥16 µg/ml	≥16 µg/ml	≤1 µg/ml	≤1 µg/ml
Amikacin	≤4 µg/ml	≤4 µg/ml	≤4 µg/ml	≤4 µg/ml
Colistin	≤0.5 µg/ml	≤0.5 µg/ml	1 µg/ml	≤0.5 µg/ml
Tigecycline	0.5 µg/ml	≤0.25 µg/ml	1 µg/ml	≤0.25 µg/ml
SXTa	≥4 µg/ml	2 µg/ml	≥4 µg/ml	2 µg/ml

^aSXT: Trimethoprim/sulfamethoxazole.

Trimethoprim/sulfamethoxazole MICs are presented according to the concentration of trimethoprim.